A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis

Archives of Dermatological Research

Volumn 304, Issue 6, 2012, Pages 459-463

  Yanaba, Koichi ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clusterin; Digital ulcer; Pulmonary arterial hypertension; Systemic sclerosis; Vasculopathy

Indexed keywords

CLUSTERIN; PENICILLAMINE; PREDNISOLONE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTRACTURE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FINGER ULCER; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VASCULAR DISEASE;

ADULT; CLUSTERIN; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 84864778093     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-012-1219-3     Document Type: Article

References (27)

1. Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 16:18-22
2. Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892-1896
3. de Silva HV, Stuart WD, Duvic CR et al (1990) A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 265:13240-13247
4. Devauchelle V, Essabbani A, De Pinieux G et al (2006) Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J Immunol 177:6471-6479
5. Falgarone G, Chiocchia G (2009) Chapter 8: clusterin: a multifacet protein at the crossroad of Inflammation and autoimmunity. Adv Cancer Res 104:139-170
6. Generini S, Matucci Cerinic M (1999) Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455:93-100
7. Hamaguchi Y, Hasegawa M, Fujimoto M et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487-495
8. Jenne DE, Tschopp J (1992) Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 17:154-159
9. Jones SE, Jomary C (2002) Clusterin. Int J Biochem Cell Biol 34:427-431
10. Jun HO, Kim DH, Lee SW et al (2011) Clusterin protects H9c2 cardiomyocytes from oxidative stress-induced apoptosis via Akt/GSK-3β signaling pathway. Exp Mol Med 43:53-61
11. Krijnen PA, Cillessen SA, Manoe R et al (2005) Clusterin: a protective mediator for ischemic cardiomyocytes? Am J Physiol Heart Circ Physiol 289:H2193-H2202
12. LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classiWcation, subsets and pathogenesis. J Rheumatol 15:202-205
13. LeRoy EC, Krieg T, Black C et al (1988) Scleroderma (systemic sclerosis): classiWcation, subsets, and pathogenesis. J Rheumatol 15:202-205
14. McLaughlin L, Zhu G, Mistry M et al (2000) Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J Clin Invest 106:1105-1113
15. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85
16. Newkirk MM, Apostolakos P, Neville C, Fortin PR (1999) Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J Rheumatol 26:597-603
17. Okano Y (1996) Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 22:709-735
18. Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393-408
19. Sato S (1999) Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 11:503-507
20. Steen V, Denton CP, Pope JE, Matucci-Cerinic M (2009) Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii19-iii24
21. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classiWcation of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
23. Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32:679-686
24. Trougakos IP, Gonos ES (2006) Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 40:1324-1334
25. Van Dijk A, Vermond RA, Krijnen PA et al (2010) Intravenous clusterin administration reduces myocardial infarct size in rats. Eur J Clin Invest 40:893-902
26. White B (1996) Immunopathogenesis of systemic sclerosis. Rheum Dis Clin Nor Am 32:695-708
27. Zhou W, Guan Q, Kwan CC et al (2010) Loss of clusterin expression worsens renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 298:F568-F578